On February 5, 2020, the Patent Trial and Appeal Board (PTAB) sided with Finnegan client Biogen, upholding a patent covering the blockbuster multiple sclerosis drug Tecfidera®. Mylan Pharmaceuticals challenged the patent in an inter partes review (IPR), but the PTAB stated Mylan failed to show that any of the challenged claims are obvious. This is not the first time Biogen’s patent has been challenged and survived review at the PTAB.
Read the full article here.
Press Release
September 11, 2024
Announcement
September 3, 2024
Announcement
Finnegan and Partner Daniel Chung Recognized by The National Law Journal
September 3, 2024
Press Release
Finnegan Named a “True Trailblazer” for Its Continued Commitment to Mansfield Certification Process
August 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.